A case of acute exacerbation of chronic spontaneous urticaria due to COVID-19 immediately after omalizumab administration.
Journal Information
Full Title: Postepy Dermatol Alergol
Abbreviation: Postepy Dermatol Alergol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Conflict of interest Hayama K has received a study grant or honoraria for being a speaker from Boehringer Ingelheim, Kyorin, Novartis, and Taiho. Fujita H has received a study grant or honoraria for being a speaker from Boehringer Ingelheim, Kyorin, Novartis, Taiho. Izaki S, Hayashi K, Kurosawa Y, Yamada S, Shimizu T and Gon Y declare no conflict of interest."
Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025